NCT01241240

Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 192 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.

Conditions

• Glaucoma, Open-Angle
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)	One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
DRUG	Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution	One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.

Timeline

• Start date: 2011-03-01
• Primary completion: 2013-09-01
• Completion: 2013-09-01
• First posted: 2010-11-16
• Last updated: 2014-09-10
• Results posted: 2014-09-10

Locations

2 sites across 2 countries: Colombia, Mexico